Targeting metabolism in pancreatic ductal adenocarcinoma: challenges and insights from the AVENGER 500 trial.

作者信息

Nakasone Elizabeth S, Coveler Andrew L

机构信息

University of Hawaii Cancer Center, University of Hawai'i at Mānoa, Honolulu, HI, USA.

Department of Medicine, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI, USA.

出版信息

J Gastrointest Oncol. 2025 Jun 30;16(3):1351-1355. doi: 10.21037/jgo-2025-61. Epub 2025 Jun 26.

DOI:10.21037/jgo-2025-61

PMID:40672105

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12261018/

Abstract

摘要

相似文献

[1]

Targeting metabolism in pancreatic ductal adenocarcinoma: challenges and insights from the AVENGER 500 trial.

J Gastrointest Oncol. 2025-6-30

[2]

Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.

J Clin Oncol. 2024-11

[3]

Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer.

JAMA Netw Open. 2024-10-1

[4]

Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial.

Blood Neoplasia. 2024-3-29

[5]

Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study.

Lancet Gastroenterol Hepatol. 2025-7

[6]

Labor-Efficient Pathological Auxiliary Diagnostic Model for Primary and Metastatic Tumor Tissue Detection in Pancreatic Ductal Adenocarcinoma.

Mod Pathol. 2025-7

[7]

Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.

J Cancer Res Clin Oncol. 2017-6

[8]

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.

Future Oncol. 2019-9-12

[9]

Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial.

Clin Pharmacol Ther. 2025-4

[10]

Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.

BMC Cancer. 2025-1-20

本文引用的文献

[1]

Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).

J Cancer Res Clin Oncol. 2024-10-1

[2]

Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.

J Clin Oncol. 2024-11

[3]

Cancer statistics, 2024.

CA Cancer J Clin. 2024

[4]

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma.

BMC Cancer. 2023-10-10

[5]

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.

Lancet. 2023-10-7

[6]

Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).

Clin Cancer Res. 2023-7-5

[7]

Pancreatic cancer incidence trends in the United States from 2000-2017: Analysis of Surveillance, Epidemiology and End Results (SEER) database.

F1000Res. 2021

[8]

Metabolism of pancreatic cancer: paving the way to better anticancer strategies.

Mol Cancer. 2020-3-2

[9]

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.

JAMA Oncol. 2019-7-1

[10]

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.

Eur J Cancer. 2019-1-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Targeting metabolism in pancreatic ductal adenocarcinoma: challenges and insights from the AVENGER 500 trial.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

本文引用的文献